Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Very Early Molecular Responses During The First Two Months Of Therapy Are Highly Predicitive Of Deep Molecular Responses In Newly-Diagnosed Chronic Myeloid Leukemia In Chronic Phase( CML-CP) Patients Treated Upfront With Nilotinib. The Spanish Substudy Of The ENEST1st Trial

Blood (2013) 122 (21): 5190.

https://doi.org/10.1182/blood.V122.21.5190.5190

Published: 2013

Journal Articles

Personalized Treatment with low doses of Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma in frail or Elderly Patients

Angel Ruedas, MD, Pablo Guisado, MD, PhD, Beatriz Aguado, MD, PhD, Ricardo Perez, MD, Joaquin Martinez, MD, J Valentin Garcia-Gutierrez, MD, PhD, M. Jesús Blanchard, MD, Pilar Bravo, MD, Carlos Montalban

Blood (2012) 120 (21): 5049.

https://doi.org/10.1182/blood.V120.21.5049.5049

Published: 2012

Journal Articles

Outcomes of Chronic Myeloid Leukemia (CML) Patients Who Stopped Second Generation Tyrosine Kinase Inhibitors (2GTKIs) As Second Line Treatment. Results of the CML Spanish National Registry (RELMC)

J Valentin Garcia-Gutierrez, MD, PhD, Begoña Maestro, Luis Felipe Casado, MD, PhD, Manuel Perez-Encinas, Isabel Massague, Raquel de Paz, Santiago Osorio, Joaquin Martinez, MD, Guiomar Bautista, MD, Pilar Giraldo, Carmen Burgaleta, Maria Jesús Peñarrubia, Maria José Requena, Carmen Calle, Jose Ángel Hernández-Rivas, Pilar Cano, Juan Luis Steegmann, MD, PhD

Blood (2012) 120 (21): 3764.

https://doi.org/10.1182/blood.V120.21.3764.3764

Published: 2012

Journal Articles

Switching to a Second Generation TKI in Chronic Myeloid Leukemia Patients with Late Suboptimal Response with Imatinib Obtained Better Molecular Responses That the “Watch and Wait” Approach. an Experience of a Multicenter Registry in Patients Outside Clinical Trials

J Valentin Garcia-Gutierrez, MD, PhD, Begoña Maestro, Luis Felipe Casado, MD, PhD, Manuel Perez-Encinas, Isabel Massague, Raquel De Paz, MD, Santiago Osorio, Joaquin Martinez, MD, Guiomar Bautista, MD, Pilar Giraldo, Carmen Burgaleta, Maria Jesús Peñarrubia, Maria José Requena, Carmen Calle, Jose Angel Hernandez-rivas, MD, Pilar Cano, Juan Luis Steegmann, MD, PhD

Blood (2012) 120 (21): 3768.

https://doi.org/10.1182/blood.V120.21.3768.3768

Published: 2012

Journal Articles

Impact of Second-Generation Tyrosine Kinase Inhibitors As Second Line Treatment for Patients with Chronic Myeloid Leukemia,

J Valentin Garcia-Gutierrez, MD, PhD, Pilar Herrera, MD, PhD, Lorena L Abalo, Maria Dolores Rey, Maria Calbacho, Lourdes Ramos, Paloma Ramos, Carlos Montalban, MD, PhD, Javier Lopez-Jimenez, MD

Blood (2011) 118 (21): 3780.

https://doi.org/10.1182/blood.V118.21.3780.3780

Published: 2011

Journal Articles

Detection of BCR-ABL Mutations in Patients with Chronic Myeloid Leukemia Treated with Imatinib. Experience of One Centre.

J. Valentin Garcia Gutierrez, Sr, Jesùs Odriozola, Javier Lopez, Pilar Herrera, Maria Calbacho, Marta Jimenez-Rolando, Maria Tenorio, Anabelle Chinea, Jose Garcia-Laraña

Blood (2009) 114 (22): 4280.

https://doi.org/10.1182/blood.V114.22.4280.4280

Published: 2009

Journal Articles

Imatinib Plasma Levels and Its Correlation with Response in Chronic-Phase Chronic Myeloid Leukemia: Experience of One Centre.

J. Valentin Garcia. Gutierrez, Sr, Jesús Odriozola, Pilar Herrera, Javier Lopez, Maria Calbacho, Marta Jimenez-Rolando, Maria Blanchard, Anabelle Chinea, Maria Tenorio, Jose García-Laraña

Blood (2009) 114 (22): 4284.

https://doi.org/10.1182/blood.V114.22.4284.4284

Published: 2009

NARROW

Very Early Molecular Responses During The First Two Months Of Therapy Are Highly Predicitive Of Deep Molecular Responses In Newly-Diagnosed Chronic Myeloid Leukemia In Chronic Phase( CML-CP) Patients Treated Upfront With Nilotinib. The Spanish Substudy Of The ENEST1st Trial

Personalized Treatment with low doses of Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma in frail or Elderly Patients

Outcomes of Chronic Myeloid Leukemia (CML) Patients Who Stopped Second Generation Tyrosine Kinase Inhibitors (2GTKIs) As Second Line Treatment. Results of the CML Spanish National Registry (RELMC)

Switching to a Second Generation TKI in Chronic Myeloid Leukemia Patients with Late Suboptimal Response with Imatinib Obtained Better Molecular Responses That the “Watch and Wait” Approach. an Experience of a Multicenter Registry in Patients Outside Clinical Trials

Impact of Second-Generation Tyrosine Kinase Inhibitors As Second Line Treatment for Patients with Chronic Myeloid Leukemia,

Detection of BCR-ABL Mutations in Patients with Chronic Myeloid Leukemia Treated with Imatinib. Experience of One Centre.

Imatinib Plasma Levels and Its Correlation with Response in Chronic-Phase Chronic Myeloid Leukemia: Experience of One Centre.

Email alerts

ASH Publications

American Society of Hematology

Very Early Molecular Responses During The First Two Months Of Therapy Are Highly Predicitive Of Deep Molecular Responses In Newly-Diagnosed Chronic Myeloid Leukemia In Chronic Phase( CML-CP) Patients Treated Upfront With Nilotinib. The Spanish Substudy Of The ENEST1st Trial

Personalized Treatment with low doses of Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma in frail or Elderly Patients

Outcomes of Chronic Myeloid Leukemia (CML) Patients Who Stopped Second Generation Tyrosine Kinase Inhibitors (2GTKIs) As Second Line Treatment. Results of the CML Spanish National Registry (RELMC)

Switching to a Second Generation TKI in Chronic Myeloid Leukemia Patients with Late Suboptimal Response with Imatinib Obtained Better Molecular Responses That the “Watch and Wait” Approach. an Experience of a Multicenter Registry in Patients Outside Clinical Trials

Impact of Second-Generation Tyrosine Kinase Inhibitors As Second Line Treatment for Patients with Chronic Myeloid Leukemia,

Detection of BCR-ABL Mutations in Patients with Chronic Myeloid Leukemia Treated with Imatinib. Experience of One Centre.

Imatinib Plasma Levels and Its Correlation with Response in Chronic-Phase Chronic Myeloid Leukemia: Experience of One Centre.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only